Articles

Innovating scientific conferences

More meetings are going virtual, and that may very well be a good thing even after COVID is no longer a pandemic
Written byPeter Kissinger
| 4 min read

Wars have been productive at accelerating innovation—even when the war is against a pandemic. Adrenaline and cash both flow in high gear under the current stress. The transition of meetings to a virtual format has accelerated from a modest pace to becoming the new standard in just four months. The tools were sufficiently developed with the hardware and bandwidth to go “all in” from elementary school to science and medicine.

The last conference I attended in person was in early March in Chicago. It could be my last. Since then, my meeting plans have been cancelled, delayed or have gone virtual. There were worries in early March, as many foreign participants could not get visas and international travel had already been deemed ill-advised. I wasn’t sure I should attend and began to muse about my experience with such meetings since the 1970s, long before email, smartphones and Zoom.

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

About the Author

Here are some related topics that may interest you:

Published In

Volume 16 - Issue 8 | September 2020

September 2020

September 2020 Issue

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Illustration of multiple three-dimensional patient-derived organoids suspended against a dark blue background, representing tumor models used in precision oncology research.
By combining organoid biology with precision automation, researchers developed a miniaturized organoid screening platform that could help speed personalized cancer treatment testing.
Illustration of multiple three-dimensional patient-derived organoids suspended against a dark blue background, representing tumor models used in precision oncology research.
By combining organoid biology with precision automation, researchers developed a miniaturized organoid screening platform that could help speed personalized cancer treatment testing.
3D illustration of a membrane protein embedded within a lipid nanodisc, representing a native-like environment used for membrane protein stabilization and characterization.
Mass photometry supports membrane protein characterization by providing rapid insights into sample composition, purity, and molecular assembly.
Drug Discovery News December 2025 Issue
Latest IssueVolume 21 • Issue 4 • December 2025

December 2025

December 2025 Issue

Explore this issue